Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.26
GRFS's Cash to Debt is ranked lower than
92% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. GRFS: 0.26 )
GRFS' s 10-Year Cash to Debt Range
Min: 0.16   Max: 0.32
Current: 0.26

0.16
0.32
Equity to Asset 0.32
GRFS's Equity to Asset is ranked lower than
84% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GRFS: 0.32 )
GRFS' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.37
Current: 0.32

0.3
0.37
Interest Coverage 4.09
GRFS's Interest Coverage is ranked lower than
94% of the 382 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GRFS: 4.09 )
GRFS' s 10-Year Interest Coverage Range
Min: 1.56   Max: 18.28
Current: 4.09

1.56
18.28
F-Score: 5
Z-Score: 2.39
M-Score: -2.48
WACC vs ROIC
3.32%
19.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 25.11
GRFS's Operating margin (%) is ranked higher than
90% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. GRFS: 25.11 )
GRFS' s 10-Year Operating margin (%) Range
Min: 15.53   Max: 26.85
Current: 25.11

15.53
26.85
Net-margin (%) 13.79
GRFS's Net-margin (%) is ranked higher than
83% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. GRFS: 13.79 )
GRFS' s 10-Year Net-margin (%) Range
Min: 2.8   Max: 16.2
Current: 13.79

2.8
16.2
ROE (%) 18.70
GRFS's ROE (%) is ranked higher than
92% of the 754 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. GRFS: 18.70 )
GRFS' s 10-Year ROE (%) Range
Min: 4.27   Max: 19.76
Current: 18.7

4.27
19.76
ROA (%) 5.91
GRFS's ROA (%) is ranked higher than
84% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -23.16 vs. GRFS: 5.91 )
GRFS' s 10-Year ROA (%) Range
Min: 1.34   Max: 6.58
Current: 5.91

1.34
6.58
ROC (Joel Greenblatt) (%) 39.30
GRFS's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: -344.23 vs. GRFS: 39.30 )
GRFS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 19.07   Max: 44.29
Current: 39.3

19.07
44.29
Revenue Growth (3Y)(%) 18.90
GRFS's Revenue Growth (3Y)(%) is ranked higher than
76% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. GRFS: 18.90 )
GRFS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 18.9   Max: 26.6
Current: 18.9

18.9
26.6
EBITDA Growth (3Y)(%) 36.80
GRFS's EBITDA Growth (3Y)(%) is ranked higher than
87% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. GRFS: 36.80 )
GRFS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 30.1   Max: 36.8
Current: 36.8

30.1
36.8
EPS Growth (3Y)(%) 104.60
GRFS's EPS Growth (3Y)(%) is ranked higher than
98% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. GRFS: 104.60 )
GRFS' s 10-Year EPS Growth (3Y)(%) Range
Min: 7.1   Max: 104.6
Current: 104.6

7.1
104.6
» GRFS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

GRFS Guru Trades in Q2 2014

Caxton Associates 87,571 sh (+239.42%)
Jim Simons 526,802 sh (+6.83%)
Steven Cohen 112,300 sh (unchged)
John Paulson 19,605,181 sh (-1.06%)
Ron Baron 42,800 sh (-4.37%)
Mario Gabelli 25,177 sh (-15.45%)
» More
Q3 2014

GRFS Guru Trades in Q3 2014

John Paulson 19,604,981 sh (unchged)
Mario Gabelli 25,177 sh (unchged)
Ron Baron 42,800 sh (unchged)
Caxton Associates Sold Out
Jim Simons 365,002 sh (-30.71%)
Steven Cohen 22,700 sh (-79.79%)
» More
Q4 2014

GRFS Guru Trades in Q4 2014

Steven Cohen Sold Out
Mario Gabelli 23,968 sh (-4.80%)
John Paulson 17,792,140 sh (-9.25%)
Ron Baron 37,800 sh (-11.68%)
Jim Simons 93,102 sh (-74.49%)
» More
Q1 2015

GRFS Guru Trades in Q1 2015

Mario Gabelli 27,868 sh (+16.27%)
John Paulson 17,801,740 sh (+0.05%)
Ron Baron 37,800 sh (unchged)
Jim Simons 77,002 sh (-17.29%)
» More
» Details

Insider Trades

Latest Guru Trades with GRFS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.30
GRFS's P/E(ttm) is ranked higher than
61% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 32.00 vs. GRFS: 26.30 )
GRFS' s 10-Year P/E(ttm) Range
Min: 17.7   Max: 95
Current: 26.3

17.7
95
Forward P/E 19.92
GRFS's Forward P/E is ranked higher than
55% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. GRFS: 19.92 )
N/A
PE(NRI) 27.10
GRFS's PE(NRI) is ranked higher than
66% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 38.20 vs. GRFS: 27.10 )
GRFS' s 10-Year PE(NRI) Range
Min: 17.65   Max: 95
Current: 27.1

17.65
95
P/B 4.00
GRFS's P/B is ranked lower than
62% of the 713 Companies
in the Global Biotechnology industry.

( Industry Median: 3.32 vs. GRFS: 4.00 )
GRFS' s 10-Year P/B Range
Min: 2.33   Max: 6.76
Current: 4

2.33
6.76
P/S 3.70
GRFS's P/S is ranked higher than
72% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: 7.28 vs. GRFS: 3.70 )
GRFS' s 10-Year P/S Range
Min: 1.87   Max: 6.66
Current: 3.7

1.87
6.66
PFCF 18.00
GRFS's PFCF is ranked higher than
70% of the 149 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GRFS: 18.00 )
GRFS' s 10-Year PFCF Range
Min: 15.55   Max: 1198.5
Current: 18

15.55
1198.5
POCF 12.95
GRFS's POCF is ranked higher than
82% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 31.11 vs. GRFS: 12.95 )
GRFS' s 10-Year POCF Range
Min: 11.01   Max: 381.13
Current: 12.95

11.01
381.13
EV-to-EBIT 18.71
GRFS's EV-to-EBIT is ranked higher than
72% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 29.86 vs. GRFS: 18.71 )
GRFS' s 10-Year EV-to-EBIT Range
Min: 11.7   Max: 47
Current: 18.71

11.7
47
PEG 1.04
GRFS's PEG is ranked higher than
84% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 2.32 vs. GRFS: 1.04 )
GRFS' s 10-Year PEG Range
Min: 0   Max: 2
Current: 1.04

0
2
Current Ratio 2.70
GRFS's Current Ratio is ranked lower than
66% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. GRFS: 2.70 )
GRFS' s 10-Year Current Ratio Range
Min: 2.7   Max: 3.36
Current: 2.7

2.7
3.36
Quick Ratio 1.59
GRFS's Quick Ratio is ranked lower than
75% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. GRFS: 1.59 )
GRFS' s 10-Year Quick Ratio Range
Min: 1.39   Max: 1.74
Current: 1.59

1.39
1.74
Days Inventory 242.28
GRFS's Days Inventory is ranked lower than
80% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 115.80 vs. GRFS: 242.28 )
GRFS' s 10-Year Days Inventory Range
Min: 235.92   Max: 713.13
Current: 242.28

235.92
713.13
Days Sales Outstanding 52.82
GRFS's Days Sales Outstanding is ranked higher than
59% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. GRFS: 52.82 )
GRFS' s 10-Year Days Sales Outstanding Range
Min: 50.97   Max: 83.07
Current: 52.82

50.97
83.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.60
GRFS's Dividend Yield is ranked lower than
51% of the 136 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GRFS: 1.60 )
GRFS' s 10-Year Dividend Yield Range
Min: 0.38   Max: 1.31
Current: 1.6

0.38
1.31
Dividend Payout 0.29
GRFS's Dividend Payout is ranked higher than
56% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GRFS: 0.29 )
GRFS' s 10-Year Dividend Payout Range
Min: 0.2   Max: 0.56
Current: 0.29

0.2
0.56
Yield on cost (5-Year) 1.60
GRFS's Yield on cost (5-Year) is ranked lower than
71% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GRFS: 1.60 )
GRFS' s 10-Year Yield on cost (5-Year) Range
Min: 0.38   Max: 1.31
Current: 1.6

0.38
1.31
Share Buyback Rate -3.60
GRFS's Share Buyback Rate is ranked higher than
71% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. GRFS: -3.60 )
GRFS' s 10-Year Share Buyback Rate Range
Min: -3.6   Max: -15.1
Current: -3.6

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.10
GRFS's Price/Median PS Value is ranked higher than
51% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. GRFS: 1.10 )
GRFS' s 10-Year Price/Median PS Value Range
Min: 0.55   Max: 1.56
Current: 1.1

0.55
1.56
Earnings Yield (Greenblatt) 5.50
GRFS's Earnings Yield (Greenblatt) is ranked higher than
92% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. GRFS: 5.50 )
GRFS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 8.6
Current: 5.5

2.1
8.6

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:GIFLF.USA, GIKLY.USA, GRF.P.Spain, 0EM7.UK, GRF.Spain, GIFOF.USA, G0FB.Germany, OZT.Germany, GRFP N.Mexico,
Grifols SA Was incorporated on June 22, 1987. It is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. The Company operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials and Others. The Bioscience division includes activities relating to the manufacture of plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation and purification of plasma, and the sale and distribution of end products. The main plasma products it manufactures are IVIG, Factor VIII, A1PI and albumin. It also manufactures intramuscular immunoglobulins, ATIII, Factor IX and plasma thromboplastin component, or PTC. The Diagnostic division focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, including analytical instruments and reagents for diagnostics, as well as blood bank products. The Company concentrates its Diagnostic business in immunohematology and hemostasis product lines. The Diagnostic division's main customers are blood donation centers, clinical analysis laboratories and hospital immunohematology services. The Raw Material division provides raw materials for its intravenous therapy products like plastic and glass bottles, which the company purchases from various European suppliers. The Hospital division manufactures and installs products used by and in hospitals, such as parenteral solutions and enteral and parenteral nutritional fluids, which are sold almost exclusively in Spain and Portugal. It also includes products that the company do not manufacture. The Company operates in Latin America, in countries such as Mexico, Colombia, Argentina, Chile and Brazil. It sells Bioscience, Diagnostic and Hospital products to hospitals and clinics, GPOs, governments and other distributors globally. The Company's operations are subject to government authorities in the United States, at the federal, state and local level, and in other countries in which it operates.
» More Articles for GRFS

Headlines

Articles On GuruFocus.com
Gold-Focused Guru John Paulson Reports First Quarter Holdings May 22 2014 
Is Grifols Being Overlooked? Mar 19 2014 
John Paulson's Top Five Holdings Nov 20 2013 
John Paulson's Top Five Holdings Sep 12 2013 
Baron Funds Comments on Grifols SA Aug 30 2012 
Friday Value Overview Aug 19 2011 

More From Other Websites
Goldman Sachs: Time To Buy Carlisle Companies And Grifols May 18 2015
Grifols’ net profit up by +6.2% to 128.5 million euros and sales grow by 13.8% in the first... May 07 2015
Grifols, S.A. downgraded by Berenberg Apr 28 2015
GRIFOLS SA Financials Apr 07 2015
Grifols 2014 Annual Report on Form 20-F filed with the SEC on April 1, 2015 Apr 01 2015
Grifols to make a major equity investment in Alkahest Mar 29 2015
Grifols to make a major equity investment in Alkahest Download (380.5 Kb) Mar 04 2015
Grifols to make a major equity investment in Alkahest Mar 04 2015
Grifols achieves a record net profit of 470.3 million euros with growth of 36.1% in 2014 Download... Feb 26 2015
4 Stocks Spiking on Unusual Volume: Novo Nordisk and More Jan 26 2015
Zacks Rank #5 Additions for Tuesday - Tale of the Tape Jan 20 2015
Grifols receives FDA approval for its new purification plant to produce Gamunex in Los Angeles... Jan 02 2015
Grifols introduces new 40-g IVIG vial size for GAMUNEX-C Dec 01 2014
3 Stocks Raising The Drugs Industry Higher Nov 04 2014
Grifols’ net profit increases by 26.9% to 339 million euros in the nine months to September 2014... Nov 04 2014
Investigating inhibitor development in patients with Hemophilia A Oct 17 2014
3 Stocks Boosting The Drugs Industry Higher Oct 16 2014
Grifols presents its GATRA scholarship program to promote research on antithrombin therapy Oct 15 2014
3 Health Services Stocks Moving The Industry Upward Aug 20 2014
3 Stocks Underperforming Today In The Health Services Industry Aug 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK